Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. - Wikidata - wikimedia - TriplyDB

Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

http://www.wikidata.org/entity/Q41826343

about

Role of exosomes/microvesicles in the nervous system and use in emerging therapies Immune Evasion Strategies of Glioblastoma Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas Regulatory myeloid cells in transplantation A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Influence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytoma Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.A nested case-control study of 277 prediagnostic serum cytokines and glioma.Strategies for improving the reporting of human immunophenotypes by flow cytometry.Overview of cellular immunotherapy for patients with glioblastoma.Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer Glioma stem cells and immunotherapy for the treatment of malignant gliomas.Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells Influence of human immune cells on cancer: studies at the University of Colorado.Immunological monitoring of the tumor immunoenvironment for clinical trials.Clinical trials in cellular immunotherapy for brain/CNS tumors.Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression.Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.Assessment of Brain Tumor Response: RANO and Its Offspring.Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.

P2860

Q21129255-9CF1D739-F672-483B-88B3-5CEB2304F6B4 Q26765855-48A09D42-5378-41C8-94CE-F58C55C394D3 Q26777205-9883A31D-3DC5-44C5-A1F1-1DD8816E9498 Q26851160-F6A6350E-C9B7-4E19-8B36-50B686C8656A Q26862551-8785F5D7-4106-4E65-986C-B10D5B111CBC Q26999875-BEBA1612-41A9-40A9-A178-42066E21B1EC Q27310807-6367749A-BE42-47D9-B4EA-FA798520E13E Q28066906-79F800CF-5603-4CC8-A96E-A3E179E963C3 Q28083009-A2880F24-DF12-4ACF-BB4B-C1ACA6452263 Q28477560-F9A0B0B2-3458-4265-90D1-BCF62BA68CD4 Q33759661-2ACAFD81-996B-4039-A8A4-D697989506F0 Q33778545-BB3271BF-2D90-4653-9A46-B264D5D1B57B Q33822690-1C20C6B9-C1B2-4E6A-975D-263023263220 Q34189694-907CCD76-151D-41D1-8EBB-422A2687B18C Q34316147-611600FC-A2A8-44E2-96C4-FA063C631087 Q34437996-ABBFAC28-3C86-46DF-AE20-ED9426CF96BB Q34557531-D62EA687-A9B5-4D8D-93DB-1D3BD3185CC4 Q35629271-9567E835-4FD6-4185-8D4C-992EC8C497A2 Q35759682-54A2D451-A8F8-42B9-97F2-210787DC24AC Q35772513-05A6227A-638B-445D-8DBE-B1C5C3886D29 Q35799695-1D9962FB-A31B-40A7-AE82-547DF11C4D74 Q35921894-9B84252A-C7A0-49B1-AFD7-208D7337532E Q35965142-D5D27E64-A1C7-456A-A2BA-46FB3A6F54AA Q36206949-560F3EEA-124B-4FCC-9AE9-BCD4A5808BC6 Q36255674-E80F53CD-3228-4AD4-8183-DE5B71EC5D54 Q36514324-0BC4548E-417C-4630-B7AC-CB950F66C835 Q36896764-E5C65517-DA23-40E0-9C7B-367157458290 Q36898699-72D46DED-0F44-4F56-BF49-43F8FAA84567 Q37079098-F8F055D0-C7FA-421A-A1F9-E08854CAF125 Q37698684-E237E2B1-928D-4E3A-9866-AD4DE4DF697D Q37955680-6B756B5F-F095-45B7-93CE-7A705A2444BD Q38094811-FB4C00AB-373C-41ED-81DC-47E333A11FAF Q38207587-E639DB66-4D4B-47BE-A41E-DB309D8B5B08 Q38344066-C2AA1A8E-A202-4CF7-8117-EB25B375230F Q38540262-E351699A-7A7B-46DA-9CA7-7A6C6E89BDE6 Q38662119-15779E53-0655-4BEE-A18D-7EB8D82B9168 Q38811369-86D9CD8B-83D0-4276-BFF5-D9EB603060D2 Q38855020-212AE86A-D9CE-4E7D-B3C0-673669F34FC1 Q38895952-12E193A8-CD38-4449-979E-1B2CD3D54925 Q38925761-B629A575-3684-45BB-80C4-A7B960ED7C6D

P2860

Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

http://www.wikidata.org/entity/Q41826343

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Systemic immune suppression in ...... or factors, and dexamethasone.

@en

type

label

Systemic immune suppression in ...... or factors, and dexamethasone.

@en

prefLabel

Systemic immune suppression in ...... or factors, and dexamethasone.

@en

P1433

Q41826343-C2CEBEC3-9F8C-4C14-9E94-34C8152E9B6B

P1476

Q41826343-D2E41896-F370-42AA-B54B-730AA25A379F

P2093

Q41826343-4FE6CBD4-1E71-45A6-AA9C-B21CA5D6F8B3

Q41826343-540D80EC-3ECB-4A1C-A8ED-B2E2D8AD1C01

Q41826343-7B6C0F06-E301-46B2-B544-44001C37C49F

Q41826343-9EDB9EAA-F73F-4045-BE35-40FF07B606C7

Q41826343-C76BAFD1-72A9-464C-86C3-8429BF5E7A3C

Q41826343-EB67730A-1F4E-42FC-BB3A-9B5B19A447A7

P2860

Q41826343-081A7310-633C-4794-AFCD-486B7B51D304

Q41826343-0FE5C908-064F-4154-86FA-E2E51165A955

Q41826343-1311FE41-97EC-4A1F-924F-56C9A8D623AD

Q41826343-13248992-9C29-408F-B8F6-A6E49DFA4E95

Q41826343-18CE59CF-2DB3-4A77-9ED6-1C59ECA23FD9

Q41826343-1A715FE8-285D-40DE-821E-B322D2869080

Q41826343-1AAD8077-3F2A-4A46-8F83-B24791F443E7

Q41826343-280CFA47-F0FB-4BB7-8936-18C7F8E2C679

Q41826343-345CB80E-0D84-49C2-B4BE-833A72E72AF0

Q41826343-44A95FAD-A01A-455C-8B95-CE46098F102D

P304

Q41826343-A24F7910-7EA9-43F8-98AF-281F30F5BE4E

P31

Q41826343-407EEB6A-8C35-4A6E-95A9-11BE0E590433

P356

Q41826343-07885E30-F6BC-4DFD-AE70-0AD10F0CBA12

P433

Q41826343-BEEE4C34-C530-4BCD-9132-3854E4FB5685

P478

Q41826343-D79267FF-D550-4D63-9078-43D1D41A6D93

P50

Q41826343-42246049-8726-47AA-BFCA-6AF627997DD3

P577

Q41826343-6EC5780B-8E39-41E1-A39A-84372C14C98A

P5875

Q41826343-EE314823-5BBC-4ED2-9627-450C684F641A

P698

Q41826343-EE02FB8B-3851-44EE-95D8-4E0EE96ED367

P921

Q41826343-9094285A-EE4A-4AEE-9B08-07A2BCA139F1

P932

Q41826343-00CC0A91-9FA0-40A3-9204-21F2AE4DC85E

P356

P1433

P1476

Systemic immune suppression in ...... or factors, and dexamethasone.

@en

P2093

Brian Patrick O'Neill

http://www.w3.org/2001/XMLSchema#string

Dennis A Gastineau

http://www.w3.org/2001/XMLSchema#string

Kent C New

http://www.w3.org/2001/XMLSchema#string

Michael P Gustafson

http://www.w3.org/2001/XMLSchema#string

Peggy A Bulur

http://www.w3.org/2001/XMLSchema#string

Yi Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP)

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

Glucocorticoids in T cell development and function*.

Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

The CD14+ CD16+ blood monocytes: their role in infection and inflammation.

Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections

Immunosuppressive drugs for kidney transplantation.

P304

631-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ001

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41548095

http://www.w3.org/2001/XMLSchema#string

P698

20179016

http://www.w3.org/2001/XMLSchema#string

P921

P932

2940665

http://www.w3.org/2001/XMLSchema#string